Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03393845 · ClinicalTrials.gov registry record · Phase 2
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
A Phase 2 study of Breast Cancer, sponsored by Nancy Chan, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 5
- Study locations
NCT03393845: Active Phase 2 study of Breast Cancer, sponsored by Nancy Chan, MD.
NCT03393845 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Nancy Chan, MD. The registered enrollment target is 47 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03393845, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Nancy Chan, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 5
- Study locations
Study Summary
Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
Primary Outcome
Clinical benefit ratio (CBR) is defined as the percentage of patients that achieve CR, PR, or stable disease for a minimum of four months. Patients will be evaluated for response by RECIST 1.1 and irRECIST.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Fulvestrant
Study Locations (5)
Michigan
- Michigan State University, Breslin Cancer Center - Lansing
Nebraska
- University of Nebraska Medical Center - Omaha
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- New York University Clinical Cancer Center - New York
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-01-29 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 2 |
What the registry record for NCT03393845 still lists
NCT03393845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03393845 lists 5 locations in 5 states (Michigan, Nebraska, New Jersey).
Frequently Asked Questions
What is clinical trial NCT03393845 about?
NCT03393845 is a clinical study titled "Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients". Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
What is the current status of trial NCT03393845?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2018-01-29. Estimated completion is 2027-09-01.
What conditions does trial NCT03393845 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03393845?
The interventions under investigation include: Pembrolizumab (DRUG), Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT03393845?
This trial is sponsored by Nancy Chan, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03393845 being conducted?
This trial has 5 study locations across Michigan, Nebraska, New Jersey, New York, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03393845's enrollment target sits among peer trials
47 832nd of 1224 higher than 391 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI